venetoclax
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
venetoclax
Jul 19, 2024, 22:19 |
Blog
Michael Wang: Strong antitumor synergy between venetoclax and A1155463
Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation…
Jul 17, 2024, 05:02 |
Blog
Clinical Insights on TLS Prophylaxis with Venetoclax in CCL
Mark Geyer, AYA Leukemia Program Leader at MSK Cancer Center, shared a post by Targeted…
Jul 13, 2024, 21:06 |
Insight
Michael Wang: CDK9 is a promising target in MCL
Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation…
Jul 9, 2024, 00:57 |
Insight
Talha Badar: Outcome after stopping venetoclax and azacitidine
Talha Badar shared on X: “American Journal of Hematology, Blood Research Journal, Wiley Online Library.…
Jul 4, 2024, 10:52 |
Insight
Myeloma Paper of the Day, July 4th, suggested by Robert Orlowski
Robert Orlowski shared a post on X: "Myeloma Paper of the Day: Patients with t(11;14)…
Jun 30, 2024, 09:41 |
Insight
MD Anderson Cancer Center’s Research Highlights
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…
Jun 29, 2024, 16:57 |
Insight
MD Anderson Research Highlights: EHA 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in…
Jun 24, 2024, 02:19 |
Insight
Nitin Jain: Pirtobrutinib Venetoclax and Obinutuzumab in First-Line treatment for CLL
Nitin Jain shared on X: . "Delighted…
Jun 21, 2024, 07:47 |
Blog
Blood Cancers Today - Is reduced-duration venetoclax in AML effective?
Blood Cancers Today shared a post on X: "Is reduced-duration venetoclax in AML effective? A study…
Jun 19, 2024, 07:28 |
Insight
Naval Daver presents findings of the ENHANCE-3 study at EHA2024 - AML Hub
AML Hub shared the following post on X: . "CONGRESS EHA2024 | Naval Daver…
Jun 18, 2024, 23:01 |
Insight
Dr. Naval Daver presented results of ENHANCE-3 study at EHA2024
Talha Badar shared on X: . "Dr. Naval Daver: Presented results of…
Jun 15, 2024, 07:20 |
Drugs
Talha Badar: Optimization of venetoclax based therapy
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared on X: “Wei: Optimization…
Jun 12, 2024, 15:07 |
Insight
Myeloma Paper of the Day, June 12th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Pre-clinical study finds acquired resistance…
Jun 6, 2024, 22:40 |
Dialogues
ASCO24 Updates: 7+3 vs Decitabine and Venetoclax: Which Treatment is Superior for Elderly Patients?
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and…
Jun 2, 2024, 23:06 |
Blog
Vincent Rajkumar: The 4 big myeloma randomized trials to watch out for ASCO24
Vincent Rajkumar shared a post on X: "The 4 big myeloma randomized trials to watch out…
Jun 2, 2024, 22:16 |
Insight
ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
Clinical trial results suggest new treatment options could reduce need for stem cell transplants and…
May 22, 2024, 01:53 |
Insight
Nitin Jain: Looking forward to presenting phase 2 trial of frontline treatment for patients with CLL at EHA 2024
Nitin Jain, Professor of the Department of Leukemia at MD Anderson Cancer Center, shared on…
May 21, 2024, 04:55 |
Drugs
Jayastu Senapati: Optimal use of Azacytidine Venetoclax in AML Patients in Indian Scenario
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared a post on X:…
May 12, 2024, 07:00 |
Blog
Ellen Madarang: We proved that treatment of 80-90 year olds with AML can be done
Ellen Madarang, Hematology Oncology Clinical Pharmacist at Sylvester Comprehensive Cancer Center, shared the following post…
May 12, 2024, 01:40 |
Insight
Justin Watts: A significant portion of patients at the extremes of older age (80-90) still derive benefit from the VEN-HMA regimen
Justin Watts et al. report that standard of care treatment for acute myeloid leukemia extends…
May 10, 2024, 00:51 |
Dialogues
OncoDaily Walk and Talk with Marina Konopleva, hosted by Tatev Margaryan
OncoDaily Walk and Talk is a series of interviews done by Tatev Margaryan, a public…
May 1, 2024, 21:39 |
Blog
It’s the one-two punch cancer treatment that ‘floats like a butterfly, and STINGs like a bee’! - WEHI (Walter and Eliza Hall Institute of Medical Research)
WEHI (Walter and Eliza Hall Institute of Medical Research) made the foll0wing post on LinkedIn:…
Apr 20, 2024, 07:03 |
Drugs
Hagop Kantarjian: Dasatinib and Venetoclax is safe and effective in newly diagnosed CML in CP
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Apr 18, 2024, 13:58 |
Insight
Ben Derman: Should MRD negativity be accepted as a surrogate endpoint for clinical trials in myeloma
Ben Derman, Assistant Professor at the University of Chicago, shared on X/Twitter: "Should MRD negativity…
Apr 17, 2024, 18:53 |
Insight
Andrius Žučenka: As a bone marrow transplanter I trully find BMT as one the most difficult and somewhat miraculous procedures
Andrius Žučenka, Hematologist, Researcher, Lecturer and PhD Candidate at Vilnius University Hospital Santaros Klinikos, shared on…
Apr 13, 2024, 09:17 |
Societies
30 Posts Not To Miss From AACR24!
The AACR Annual Meeting 2024 was held from April 5th to 10th in San Diego,…
Apr 5, 2024, 08:22 |
Insight
Hagop Kantarjian: Low-dose azacitidine plus venetoclax - in patients with AML unable to complete standard consolidation strategies
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Mar 27, 2024, 21:12 |
Insight
Naveen Pemmaraju: Our new collaborative report CD38 and BCL2 guided therapy in BPDCN
Naveen Pemmaraju posted on X/Twitter: "Excited to share our interesting new collaborative report CD38 and BCL2…
Mar 10, 2024, 20:49 |
Insight
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University…
Feb 13, 2024, 08:00 |
Blog
Talha Badar: Brief review focusing on VEN and HMA triplets in AML
Talha Badar, Hematologist/Oncologist at Mayo Clinic in Jacksonville, Florida, shared a thread on X/Twitter: "Weekend…
Feb 6, 2024, 04:40 |
Blog
Talha Badar: Weekend review. Venetoclax for NPM1m
Talha Badar, Hematologist/Oncologist at Mayo Clinic in Jacksonville, Florida, shared a post on X/Twitter: "Weekend…
Jan 27, 2024, 08:05 |
Blog
Talha Badar: Outcome of patients progressing after venetoclax based therapies
Talha Badar, Hematologist/Oncologist at Mayo Clinic in Jacksonville, Florida, shared a post on X/Twitter: "…
Jan 19, 2024, 18:16 |
Blog
Satya Prakash Yadav: Is chemotherapy free treatment of leukemia possible?
Satya Prakash Yadav, Director of Paediatric Hemato-Oncology and Bone Marrow Transplant at Medical and Haemato-Oncology…
Jan 18, 2024, 11:27 |
Insight
Hagop Kantarjian: Hyper-CVD + venetoclax achieves CR/CRi rate of 57% in heavily treated relapsed/refractory Acute Lymphoblastic Leukemia
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson…
Jan 18, 2024, 10:38 |
Insight
Nicola Gökbuget: Time to acknowledge the very successful presentations of the German Multicenter Study Group for Adult ALL
Nicola Gökbuget, Head of Clinical Trial Center at Goethe University Hospital, posted on LinkedIn: "The…
Jan 9, 2024, 19:11 |
Blog
Talha Badar: What is the right duration of VENETOCLAX with HMA for AML
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:…
Jan 5, 2024, 17:36 |
Insight
Talha Badar: What is the right duration of Venetoclax with HMA for AML?
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, shared on X/Twitter:…
Dec 24, 2023, 18:42 |
Insight
Naveen Pemmaraju: Important new paper led by Alex Bataller and Tapan Kadia
Naveen Pemmaraju shared on X/Twitter: "Important New paper just out in Blood Advances led by…
Dec 21, 2023, 17:24 |
Blog
Natalia Baran: Metabolic Rewiring of leukemic cells upon gaining resistance to AraC
Natalia Baran, Assistant Professor in the Department of Leukemia at the UT MD Anderson Cancer…
Dec 16, 2023, 17:53 |
Drugs
Guillaume Carpentier: Outstanding talk by Tapan Kadia on all oral tx with Dec-C plus Venetoclax in pts with AML ineligible for IC
Guillaume Carpentier, Assistant Professor in the Department of Medicine, Division of Hematology at Queen's University,…
Dec 12, 2023, 18:37 |
Blog
Klaus Metzeler: Some of my (secret) favourites in the AML/MDS field
Klaus Metzeler, Professor of Translational Haematology at University of Leipzig, shared on X/Twitter: “As the ASH 23…
Nov 13, 2023, 13:43 |
Drugs
Jayastu Senapati: Check out the commentary to our paper in the Blood Journal by Paresh Vyas
Jayastu Senapati, Leukemia fellow at MD Anderson Cancer Centre, shared on X/Twitter: "Check out the…
Oct 3, 2023, 17:43 |
Drugs
,
Insight
Rafael Fonseca: The clinical development curse against venetoclax for t(11;14) multiple myeloma.
Rafael Fonseca, the Chief Innovation Officer at Mayo Clinic, Arizona, recently tweeted on X/Twitter: ''The…
Sep 27, 2023, 18:06 |
Drugs
Hagop Kantarjian: Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.
Aug 29, 2023, 19:15 |
Insight
Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.
Andres Gomez, an Associate Professor at Universidad Autónoma de Nuevo León, Mexico, recently tweeted: "Venetoclax…
Jul 18, 2023, 19:39 |
Drugs
Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML
Quoting Hagop Kantarjian on Twitter, "MD Anderson Cancer Center's Leukemia researchers identify the use of venetoclax…
Jul 7, 2023, 09:51 |
Opinion
How I do venetoclax+azacitidine induction AML - Aaron Goodman
How I do venetoclax+azacitidine induction AML Ven 400 mg* days 1-28+aza 75mg/m2 days 1-7 BMBx…
All:
47
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube